Glenmark and Teva want a Pennsylvania federal judge to reject the U.S. Department of Justice's proposed January 2022 trial date for criminal price-fixing charges against the generic drugmakers, arguing there's "no reason to rush" the complicated case.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conference Call Information
ACCESSWIRE
Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT
NORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. ( Elite or the Company )(OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2021 ( Fiscal 2021 ).
Consolidated revenues for Fiscal 2021 were $25.4 million, an increase of $7.4 million or approximately 41% from the comparable period of the prior fiscal year. The increase in revenues was primarily attributed to revenues from generic immediate-release Adderall®, generic extended-release Adderall®, generic Dantrolene Capsules, and strong revenues relating to Isradipine sales capsules. Operating profits were $2.1 million, an increase of $4.3 million from the comparable period of the prior year, and net income was $5.1
Glenmark, Teva In No Rush For January 2022 Criminal Trial law360.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from law360.com Daily Mail and Mail on Sunday newspapers.
Mumbai (Maharashtra) [India], May 31 (ANI/PRNewswire): EBITDA growth of 22.7 per cent to Rs 20,844 Mn with margins of 19 per cent. Consolidated Net Profit of Rs 9,701 Mn with growth of 25 per cent in FY21.
Read more about Glenmark Pharma Q4 PAT gains 6% to Rs 234 cr on Business Standard. On a consolidated basis, the drug maker s net profit rose 6.2% to Rs 233.87 crore on 4.4% increase in net sales to Rs 2,829.89 crore in Q4 March 2021 over Q4 March 2020.